Low-dose Aspirin Linked to Reduced Liver Cancer Risk

New analysis on aspirin use and liver cancer risk was conducted by a team led by investigators at the Karolinska Institutet, in Sweden, and Massachusetts General Hospital (MGH).

Low-dose aspirin reduces the risk of death from liver-related causes among risky patients, according to the study published in the New England Journal of Medicine.

"Rates of liver cancer and of mortality from liver disease are rising at an alarming pace in U.S. and European countries. Despite this, there remain no established treatments to prevent the development of liver cancer, or to reduce the risk of liver-related death," said lead author Tracey Simon, MD, MPH, investigator in the Division of Gastroenterology and Hepatology at MGH.

Low-dose Aspirin May Down the risk of Preterm Births in First-time Mothers
New clinical trial, which involved more than 11,000 women in several low- and middle-income countries, found that women taking low-dose aspirin were 11% less likely to deliver before the 37th week of pregnancy.

TOP INSIGHT

Low-dose aspirin benefits were seen regardless of sex, the severity of hepatitis, or the type of hepatitis virus. The risk of internal bleeding was not significant among users.
Read More..

For the analysis, investigators examined information from Swedish registries on 50,275 adults who had chronic viral hepatitis, a type of liver infection that is caused by the hepatitis B or C virus and is the most common risk factor for liver cancer.

Over a median follow-up of nearly 8 years, 4.0% of patients who took low-dose aspirin (less than 163mg/day) and 8.3% of nonusers of aspirin developed liver cancer. Aspirin users had a 31% lower relative risk of developing liver cancer.

Importantly, the study showed that the longer a person took low-dose aspirin, the greater the benefit. Compared with short-term use (3 months to 1 year), the risk of liver cancer was 10% lower for 1-3 years of use, 34% lower for 3-5 years of use, and 43% lower for 5 or more years of use.

Also, liver-related deaths occurred in 11.0% of aspirin users compared with 17.9% of nonusers over 10 years, for a 27% lower risk.

The benefits were seen regardless of sex, the severity of hepatitis, or the type of hepatitis virus (B or C). The risk of internal bleeding--a concern when taking aspirin long-term--was not significantly elevated among aspirin users.

"This is the first large-scale, nationwide study to demonstrate that the use of aspirin is associated with a significantly reduced long-term risk of liver cancer and liver-related mortality," said senior author Jonas F. Ludvigsson, MD, Ph.D., of the Department of Medical Epidemiology and Biostatistics at the Karolinska Institutet.

The investigators noted that prospective randomized controlled trials are needed to test the benefits of aspirin for patients affected by liver disease.

Source-Eurekalert